Literature DB >> 7676497

Coincidence of Epstein-Barr virus reactivation, cytomegalovirus infection, and rejection episodes in renal transplant recipients.

M W Hornef1, G Bein, L Fricke, J Steinhoff, H J Wagner, W Hinderer, H H Sonneborn, H Kirchner.   

Abstract

Reactivation of the Epstein-Barr virus was reported to occur frequently under immunosuppressive therapy following organ transplantation. However, little is known about the clinical significance of these EBV reactivations. Therefore, we searched for correlations among the treatment with various immunosuppressive drugs, the incidence of CMV infections, rejection crises, and serological signs of EBV reactivation. EBV-specific antibodies were measured with novel ELISAs, utilizing the recombinant antigens p72 (for anti-EBV nuclear antigen [EBNA]1-IgG), p54, and p138 (anti-early antigen [EA]-IgM, -IgG, -IgA) in a follow-up study of 79 renal transplant recipients. Patients receiving antithymocyte globulin or antilymphocyte globulin therapy showed increasing anti-EA-IgG and -IgA more often than did patients not receiving antithymocyte globulin or antilymphocyte globulin therapy (P < 0.05). In patients receiving OKT3 antirejection therapy, anti-EA-IgM seroconversion was found more frequently (P < 0.01). A significant correlation was also found between groups of patients who had had at least one rejection episode versus patients without any sign of organ rejection, and the incidence of increasing anti-EA-IgG (P < 0.05). Since in most of these patients signs of EBV reactivation followed the appearance of the rejection episode, this may not be due to viral-induced rejection but may be caused by the reinforced immunosuppression during antirejection therapy. As opposed to patients with no signs of CMV infection and with nonsymptomatic CMV infection, patients undergoing symptomatic CMV infection showed anti-EA-IgM seroconversion (P < 0.01), increasing anti-EA-IgA (P < 0.01), and decreasing anti-EBNA-IgG (P < 0.01) more frequently. Our results confirm the role of immunosuppressive therapy in the pathogenesis of EBV reactivation. We further demonstrate a striking coincidence of EBV reactivation and symptomatic CMV infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7676497     DOI: 10.1097/00007890-199509000-00013

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  16 in total

1.  Oligo-monoclonal immunoglobulins frequently develop during concurrent cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections in patients after renal transplantation.

Authors:  E Drouet; C Chapuis-Cellier; S Bosshard; C Verniol; A Niveleau; J L Touraine; J L Garnier
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

Review 2.  The role of immunosuppression in lymphoma formation.

Authors:  I Penn
Journal:  Springer Semin Immunopathol       Date:  1998

Review 3.  Infections in solid-organ transplant recipients.

Authors:  R Patel; C V Paya
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

4.  Predictive value of quantitative PCR-based viral burden analysis for eight human herpesviruses in pediatric solid organ transplant patients.

Authors:  X Bai; B B Rogers; P C Harkins; J Sommerauer; R Squires; K Rotondo; A Quan; D B Dawson; R H Scheuermann
Journal:  J Mol Diagn       Date:  2000-11       Impact factor: 5.568

5.  ICAM-1, soluble-CD23, and interleukin-10 concentrations in serum in renal-transplant recipients with Epstein-Barr virus reactivation.

Authors:  M W Hornef; G Bein; D Wilhelm; L Fricke; H Kirchner
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

Review 6.  New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.

Authors:  I G Sia; R Patel
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

7.  Evaluation of 12 commercial tests for detection of Epstein-Barr virus-specific and heterophile antibodies.

Authors:  A L Bruu; R Hjetland; E Holter; L Mortensen; O Natås; W Petterson; A G Skar; T Skarpaas; T Tjade; B Asjø
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

8.  Immunoglobulin G, A, and M responses to BK virus in renal transplantation.

Authors:  Parmjeet S Randhawa; Gaurav Gupta; Abhay Vats; Ron Shapiro; Raphael P Viscidi
Journal:  Clin Vaccine Immunol       Date:  2006-09

9.  On the crossroad between tolerance and posttransplant lymphoma.

Authors:  Michael A Nalesnik; Thomas E Starzl
Journal:  Curr Opin Organ Transplant       Date:  1997-10-01       Impact factor: 2.640

10.  Molecular parameters for precise diagnosis of asymptomatic Epstein-Barr virus reactivation in healthy carriers.

Authors:  Susanne Maurmann; Lutz Fricke; Hans-Joachim Wagner; Peter Schlenke; Holger Hennig; Jürgen Steinhoff; Wolfram J Jabs
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.